Brandon Frith's questions to Intellia Therapeutics Inc (NTLA) leadership • Q2 2025
Question
On behalf of Andy Chen at Wolfe Research, Brandon Frith asked what specific data Intellia aims to generate with the expanded MAGNITUDE study to be compelling to payers and physicians.
Answer
EVP & CMO David Lebwohl explained that as tafamidis becomes the standard of care, it is critical to demonstrate a statistically significant and clinically meaningful benefit on top of it. CEO John Leonard added that the goal is to generate "absolutely unambiguous" data across the entire treatment spectrum—monotherapy, combination therapy, and standard of care—to clearly differentiate the product in the market.